Jane Street
RPRX icon

Jane Street’s Royalty Pharma RPRX Stock Holding History

Jane Street’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.33M Buy
194,400
+155,000
+393% +$6.79M ﹤0.01% 2627
2025
Q4 		$1.52M Sell
39,400
-134,800
-77% -$5.14M ﹤0.01% 5315
2025
Q3 		$6.15M Sell
174,200
-14,900
-8% -$539K ﹤0.01% 3111
2025
Q2 		$6.81M Buy
189,100
+34,300
+22% +$1.14M ﹤0.01% 2608
2025
Q1 		$4.82M Buy
154,800
+69,400
+81% +$2.2M ﹤0.01% 2991
2024
Q4 		$2.18M Buy
85,400
+7,100
+9% +$188K ﹤0.01% 3955
2024
Q3 		$2.22M Buy
78,300
+9,200
+13% +$255K ﹤0.01% 4263
2024
Q2 		$1.82M Buy
69,100
+43,800
+173% +$1.21M ﹤0.01% 4648
2024
Q1 		$768K Sell
25,300
-82,300
-76% -$2.43M ﹤0.01% 5893
2023
Q4 		$3.02M Buy
107,600
+6,400
+6% +$176K ﹤0.01% 3626
2023
Q3 		$2.75M Buy
101,200
+52,700
+109% +$1.57M ﹤0.01% 3512
2023
Q2 		$1.49M Sell
48,500
-298,200
-86% -$10.1M ﹤0.01% 4602
2023
Q1 		$12.5M Sell
346,700
-166,400
-32% -$6.17M 0.01% 1416
2022
Q4 		$20.3M Sell
513,100
-134,500
-21% -$5.61M 0.01% 999
2022
Q3 		$26M Buy
647,600
+95,600
+17% +$4.08M 0.01% 874
2022
Q2 		$23.2M Buy
552,000
+333,900
+153% +$13.7M 0.01% 1005
2022
Q1 		$8.5M Sell
218,100
-120,100
-36% -$4.72M ﹤0.01% 2204
2021
Q4 		$13.5M Sell
338,200
-74,100
-18% -$2.88M ﹤0.01% 1547
2021
Q3 		$14.9M Buy
412,300
+292,900
+245% +$11.4M 0.01% 1358
2021
Q2 		$4.89M Sell
119,400
-377,200
-76% -$16M ﹤0.01% 2672
2021
Q1 		$21.7M Buy
496,600
+356,100
+253% +$16.9M 0.01% 911
2020
Q4 		$7.03M Buy
140,500
+127,100
+949% +$5.39M ﹤0.01% 1729
2020
Q3 		$564K Buy
+13,400
New +$575K ﹤0.01% 4964

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jane Street's RPRX Position: Q1 2026 in Review

Jane Street reduced its Royalty Pharma (RPRX) stake by 51% in Q1 2026, selling an estimated $112M and leaving 2,400,382 shares worth $115M. The position accounts for 0.01% of the portfolio, ranked #580.

Jane Street first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $191M in Q4 2025. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Jane Street held 2,400,382 shares of Royalty Pharma worth $115M as of Q1 2026.
  • Jane Street sold 2,547,027 Royalty Pharma shares in Q1 2026, an estimated $112M.
  • Royalty Pharma made up 0.01% of Jane Street's portfolio in Q1 2026, its #580 holding.
  • Jane Street first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Jane Street's Royalty Pharma position peaked at $191M in Q4 2025.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.